Table 2.
Clinical characteristics and GH responses to ITT, GHRHarg and baseline IGF-I SDS values in the entire cohort based on the underlying etiology and the number of pituitary deficits.
| Study Population | Diagnosis | Pituitary Defects | ||||
|---|---|---|---|---|---|---|
| n = 88 | IGHD n = 29 | CGHD n = 15 | TGHD n = 44 | iGHD n = 54 | MPHD n = 34 | |
| Sex (M/F) | 49/39 | 17/12 | 6/9 | 26/18 | 32/22 | 17/17 |
| Age (yrs) | 17.2 (16.0 to 18.8) | 17.9 (16.3 to 19.1) | 17.6 (16.0 to 20.2) | 16.9 (15.6 to 18.2) | 17.2 (16.1 to 18.8) | 17.3 (15.6 to 18.6) |
| Height (SDS) | −1.1 (−2.0 to −0.3) | −0.9 (−1.7 to −0.2) | −0.6 (−2.1 to −0.04) | −1.3 (−2.2 to −0.5) | −1.4 (−2.2 to −0.4) | −0.8 (−1.4 to −0.3) |
| Target Height (SDS) | −0.4 (−1.0 to 0.3) (n = 69) | −1.0 (−1.9 to 0.3) (n = 19) | −0.4 (−0.7 to 0.03) (n = 9) | −0.3 (−0.9 to 0.4) (n = 41) | −0.5 (−1.0 to 0.2) (n = 41) | −0.4 (−1.0 to 0.5) (n = 28) |
| BMI (kg/m2) c, d | 22.7 (20.1 to 25.5) | 20.2 (19.2 to 23.0) | 23.5 (19.8 to 27.9) | 24.1 (21.0 to 26.6) | 21.4 (19.3 to 24.1) | 24.6 (22.1 to 26.7) |
| BMI (SDS)b, c | 0.9 (−0.2 to 1.6) | −0.04 (−0.8 to 1.0) | 1.3 (−0.3 to 2.2) | 1.3 (0.6 to 1.9) | 0.4 (−0.6 to 1.3) | 1.4 (0.6 to 2.1) |
| GH peak ITT (μg/L)a, b | 6.5 (1.6 to 14.4) | 17.1 (11.4 to 22.4) | 1.4 (0.1 to 7.9) | 3.1 (1.4 to 6.8) | 10.5 (4.6 to 17.3) | 2.1 (1.0 to 4.9) |
| GH peak GHRHArg (μg/L)a, b) | 17.4 (6.9 to 40.0) | 40.0 (31.4 to 40.0) | 6.7 (2.5 to 19.6) | 10.8 (5.8 to 19.7) | 30.0 (16.6 to 40.0) | 7.5 (3.6 to 13.0) |
| IGF–I (SDS)b, c | −1.1 (−2.4 to −0.2) | −0.5 (−1.1 to 0.4) (n = 27) | −2.4 (−4.6 to −1.0) (n = 15) | −1.6 (−3.1 to −0.5) (n = 43) | −0.7 (−1.7 to 0.1) | −2.2 (−3.8 to −0.7) |
IGHD, Idiopathic GHD; CGHD, congenital GHD; TGHD, tumoral GHD, iGHD, isolated; MPHD, multiple pituitary hormone deficiency.
Results are expressed as median (first quartile – third quartile).
P-value by Kruskal-Wallis (IGHD vs. TGHD vs. CGHD) = a < 0.001; c < 0.01; by Mann-Whitney (iGHD vs. MPHD) b < 0.001; d < 0.01.